Monika Graeser

A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

Monika Graeser, Afshan McCarthy, Christopher J. Lord et al. · Clinical Cancer Research · 2010 · 326 citations · Full text

Medicine, Cancer Biology, Oncology +12

Contralateral Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers

Monika Graeser, Christoph Engel, Kerstin Rhiem et al. · Journal of Clinical Oncology · 2009 · 313 citations

Medicine, Oncology, Breast Oncology +15

Noninvasive Detection of <i>HER2</i> Amplification with Plasma DNA Digital PCR

Heidrun Gevensleben, Isaac García-Murillas, Monika Graeser et al. · Clinical Cancer Research · 2013 · 171 citations

Medicine, Genetics, Oncology +17

The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study

Kerstin Rhiem, Christoph Engel, Monika Graeser et al. · Breast Cancer Research · 2012 · 127 citations · Full text

Medicine, Oncology, Breast Oncology +14

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

Ulrike Nitz, Oleg Gluz, Monika Graeser et al. · The Lancet Oncology · 2022 · 83 citations

Medicine, Oncology, Pharmacology +17